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Primary open-angle glaucoma (POAG) is a leading cause of
irreversible vision loss worldwide, with elevated intraocular pres-
sure (IOP) a major risk factor. Myocilin (MYOC) dominant gain-of-
function mutations have been reported in ∼4% of POAG cases.
MYOC mutations result in protein misfolding, leading to endoplas-
mic reticulum (ER) stress in the trabecular meshwork (TM), the tis-
sue that regulates IOP. We use CRISPR-Cas9–mediated genome
editing in cultured human TM cells and in a MYOC mouse model
of POAG to knock down expression of mutant MYOC, resulting in
relief of ER stress. In vivo genome editing results in lower IOP and
prevents further glaucomatous damage. Importantly, using an ex
vivo human organ culture system, we demonstrate the feasibility
of human genome editing in the eye for this important disease.
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Glaucoma is a multifactorial disease, with increased in-traocular pressure (IOP) as a major risk factor (1, 2). With
the advent of efficient genome editing tools, it is now reasonable to
think that the genomic component of glaucoma can be targeted for
therapeutic and prophylactic purposes. Mutations in the myocilin
gene (MYOC) have been shown to cause juvenile open-angle
glaucoma, an early-onset form of primary open-angle glaucoma
(POAG), as well as adult-onset POAG, and exhibit autosomal
dominant inheritance (3–8). Almost 100 different pathogenic
MYOC mutations have been identified, most of which are clus-
tered in exon 3 encoding the olfactomedin domain (9). Myocilin
mRNA and/or protein are expressed in eye structures including the
retina, ciliary body, and trabecular meshwork (10–12), as well as in
skeletal muscles, heart, brain, and testes (13–15), but the secreted
protein does not appear to be necessary for ocular health, as both
knockout animals and humans with homozygous, likely null mu-
tations are not associated with glaucoma phenotypes (16–19).
Various knockin and knockout mouse models indicate that
MYOC mutations are gain-of-function mutations (16, 20). Mo-
lecular and biochemical studies have shown that mutant myocilin
accumulates inside cells instead of being secreted, resulting in
activation of the unfolded protein response (UPR) cascade and
ER stress (21–23). The UPR usually results in decreased trans-
lation and increased chaperone levels to promote proper folding
and secretion of proteins (24); however, under a high burden of
misfolding, cells undergo apoptosis. Trabecular meshwork (TM)
cells are believed to be sensitive to chronic ER stress, ultimately
dying, leading to elevated IOP and glaucoma in patients with
MYOC mutations (22, 25, 26).
Novel approaches to treatment based on molecular mecha-
nisms have been directed at the use of chemical chaperones to
reduce protein misfolding and increase mutant myocilin secre-
tion (27–30). These strategies have been successful in animal
models of myocilin-associated glaucoma, and if delivered to
human patients might provide short-term relief of ER stress,
which likely will require chronic treatment. Another way to ap-
proach this treatment, especially given the gain-of-function na-
ture of MYOC mutations, is by targeting the MYOC mRNA or
protein itself (transcription or translational inhibition). While
siRNA and shRNA provide potentially viable treatment op-
tions (31), we elected to directly target the MYOC gene using
gene editing with clustered regularly interspaced short palindromic
repeats (CRISPR)-Cas9 technology to treat myocilin-associated
glaucoma.
Originally part of the prokaryotic adaptive immune system, the
CRISPR-Cas9 system has been adapted as a genome-editing tool,
in which the Cas9 endonuclease is directed by a guide RNA
(gRNA) to cleave a 23-bp DNA sequence that contains a target-
specific 20-bp sequence plus an adjacent NGG nucleotide motif,
protospacer-adjacent motif (PAM) (32). DNA double-strand
breaks (DSBs) induced by Cas9 nuclease can be repaired by two
endogenous cellular repair processes: nonhomologous end-joining
(NHEJ) and homology-directed repair (HDR). NHEJ is usually
an error-prone process causing small insertions and deletions
(indels) resulting from DNA ligation at the break sites. These
indels can cause frame shift mutations in coding regions, resulting
in an early stop codon leading to premature termination (32). In
contrast, HDR is a less error-prone process relying on high se-
quence homology between the mutant and intact donor DNA
strands. For gene therapy purposes, donor DNA or repair tem-
plate is usually a wild-type (WT) copy of the gene with homology
arms starting at the Cas9-induced DSB. As can be imagined,
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NHEJ has better efficiency than HDR with the currently
available tools.
The simplicity of its design and flexibility in targeting candidate
genes with gRNA sequences makes CRISPR-Cas9 promising as an
in vivo genome-editing tool. We sought to use the CRISPR-
Cas9 system to disrupt the MYOC gene and its aberrant function in
human and mouse TM cells and in a mouse model of primary open
glaucoma (Tg-MYOCY437H) that has been previously characterized in
our laboratories (30). We aimed to design our gRNA near the start
codon of human MYOC (exon1) to introduce an early frame shift
mutation, resulting in termination of the protein. This proof-of-
principle study of disruption of gene function should be equally ef-
fective for various MYOC mutations. Easy access to the TM of the
eye, the dominant gain-of-function nature of MYOC mutations, and
better efficiency of NHEJ compared with HDR also make this ap-
proach appealing for the treatment of myocilin-associated glaucoma.
Results
CRISPR-Mediated Gene Editing of MYOC in Vitro. We generated NTM5
(normal trabecular meshwork 5) cell lines stably expressing wild-type
and mutantMYOC containing the Y437H mutation (one of the most
common MYOC mutations leading to early-onset POAG) (Fig. S1).
Both WT and mutant myocilin were DsRed-tagged. Both WT and
mutant cell lines express higher levels of myocilin compared with naïve
control cell lines (Fig. S1). While mutant myocilin accumulates in the
cell, WT myocilin is secreted into the conditioned medium. Both WT
and mutant myocilin are posttranslationally modified by cleavage of
the N-terminal signal sequence (shorter isoform) and/or glycosylation
and thus sometimes appear as two bands on a Western blot (33, 34).
Accumulation of mutant myocilin, visible as DsRed on immunocyto-
chemistry (ICC) in Fig. S1D, leads to up-regulation of ER stress
mRNA and proteins including BiP, calnexin, PDI, ATF4, and CHOP,
as demonstrated by qPCR, Western blot analysis, and ICC (Fig. S1).
Similar levels of both WT and mutant MYOC mRNA indicate that
the changes in protein handling are posttranscriptional. These data
confirm previous findings indicating that mutant myocilin accumulates
inside glaucomatous TM cells and TM cells from transgenic mouse
models expressing a human MYOC mutation (22, 30).
Adenovirus with CRISPR assembly (Ad5-crMYOC)-mediated
transduction of NTM5 cell lines stably expressing mutant myocilin
reduces levels of myocilin and associated key UPR markers, such as
BiP, Calnexin, and PDI mRNA (Fig. 1A), as well as protein levels
(Fig. 1B). Ad5-cas9 control does not contain any gRNA and expresses
only Cas9. β-actin and Cas9 were used as internal loading controls.
Densitometric analysis showed statistically significant differences in
myocilin, BiP, Calnexin, and PDI protein levels between Ad5-cas9–
and Ad5-crMYOC–treated samples (Fig. 1C). We observed a de-
crease in myocilin-positive cells with Ad5-crMYOC treatment
(marked by circles in Fig. 1D). Quantification of Cas9-positive and
myocilin-negative cells showed a significant increase in Ad5-crMYOC–
treated samples compared with Ad5-cas9–treated samples (Fig. 1E).
Since Cas9 from Ad5-cas9 control virus is GFP-tagged, we found a
more robust staining pattern compared with that of Cas9 from the
Ad5-crMYOC virus, but both showed nuclear staining. Assuming that
every transduced cell expresses Cas9, we found ∼60–70% trans-
duction efficiency using Ad5-cas9 and/or Ad5-crMYOC by quantifying
Cas9-GFP–expressing cells. ICC showed decreased BiP, Calnexin, and
PDI expression with Ad5-crMYOC treatment (Fig. 1F). A GeneArt
genomic cleavage assay (described inMaterials and Methods) revealed
a cleavage product in Ad5-crMYOC–treated DNA samples, but not in
Ad5-cas9–treated DNA samples (Fig. 1G), indicating that our gRNA
targeted the MYOC gene. The absence of cleavage products in pre-
dicted off-target sites (TRIM45, RAB36, PLA2G6, NCLN, and NEB)
also demonstrates that the gRNA is specific to MYOC (Fig. 1H).
DNA sequencing of treated cells revealed that the most common
change observed with the MYOC-specific gRNA is a 7-bp deletion
(3 bp upstream of PAM sequence) in MYOC (Fig. 1I).
CRISPR-Cas9 Lowers IOP and Prevents Further Glaucomatous Damage
in Vivo.Our laboratory has previously developed and characterized
a mouse model of POAG (Tg-MYOCY437H) due to expression of a
human MYOC mutation (Y437H) in a human MYOC transgene
(30). Tg-MYOCY437H mice exhibit elevated IOP, retinal ganglion
cell (RGC) death and dysfunction, and optic nerve axonal de-
generation, matching the phenotype seen in patients with POAG.
We also showed that mutant myocilin is not secreted into the
aqueous humor but rather accumulates inside TM cells, inducing
ER stress in Tg-MYOCY437H mice. In the present study, we spe-
cifically targeted human mutant myocilin transgene with our Ad5-
crMYOC virus injected intravitreally (2 × 107 pfu/eye). We treated
a cohort of young Tg-MYOCY437H mice (age ≤1 mo) before the
onset of elevated IOP with either Ad5-crMYOC or Ad5-cas9
(control) to determine whether this treatment could prevent
IOP elevation. The results indicate that Ad5-crMYOC treatment
prevents IOP elevation compared with Ad5-cas9–treated eyes,
Fig. 1. MYOC disruption by CRISPR-Cas9 in vitro. (A) Ad5-crMYOC treatment
of stably transfected NTM5 cell lines overexpressing a mutant (MT) form of
human MYOC decreases myocilin (MYOC), BiP (HSP5), Calnexin (CANX), PDI
(PDIA2), ATF4 (ATF4), and CHOP (DDIT3) mRNA expression (n = 5). (B) Repre-
sentative Western blot showing that Ad5-crMYOC decreases mutant myocilin
and associated BiP, Calnexin, and PDI (n = 5). Cas9 and β-actin served as
loading controls. (C) Densitometry showing significant decreases in myocilin,
BiP, Calnexin, and PDI. (D) ICC showing that Ad5-crMYOC treatment decreases
myocilin (n = 5). Most of the Cas9 (green)-positive cells are MYOC (red)-neg-
ative (denoted by circles in the last panel). (Scale bar: 20 μm.) (E) Quantification
of Cas9-positive but myocilin-negative cells showing a significant increase in
numbers after Ad5-crMYOC treatment. (F) Ad5-crMYOC–mediated decrease in
myocilin (red) and associated BiP, Calnexin, and PDI levels (green; ICC). (Scale
bar: 100 μm.) (G) GeneArt Genomic Cleavage assay showing cleavage bands
from theMYOC PCR product (arrows) in Ad5-crMYOC–treated DNA in all three
cell lines: control (CT), WT, and mutant (MT). (H) GeneArt genomic cleavage
assay showing no cleavage bands from predicated off-target sites in PLA2G6,
NCLN, and NEB, confirming gRNA specificity for the MYOC gene. (I) Clonal
sequencing of the PCR product from Ad5-crMYOC treated samples revealing
the most common 7-bp (ATGTGGG) deletion. The error bars represent SEM.
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, one-way ANOVA or paired
Student’s t test.
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in which IOP increases with age (Fig. 2A). IOP values in
Ad5-cas9 virus-injected eyes coincide with previously reported
values (in a similar age group) in this model (30), suggesting that
Ad5-cas9 does not resolve or worsen the phenotype and serves as
a true control. We also injected a small cohort of 1- to 2-mo-old
WT mice eyes with Ad5-cas9 and/or Ad5-crMYOC virus and did
not observe any significant IOP changes. Mean nighttime IOP
was 16 mm Hg and 15 mm Hg in 2-mo-old Ad5-cas9– and Ad5-
crMYOC–injected eyes, respectively (n = 5). The mean nighttime
IOP in untreated Tg-MYOCY437H mice (n = 4; ∼4 mo old) was
20 mm Hg, similar to values reported in previous studies (29, 30).
Targeting myocilin with Ad5-crMYOC also lowered high IOP in
a cohort of older Tg-MYOCY437H mice (age ≥9 mo) as early as
2 wk postinjection (Fig. 2B). The IOP in Ad5-crMYOC–treated
eyes remained significantly lower out to 2 mo posttreatment (Fig.
3B). This suggests the presence of a pool of stressed TM cells that
stay viable but poorly functional for long periods and, when cor-
rected, have better proliferation ability and are able to repopulate
the damaged TM. It is known that TM health and/or function is
compromised in Tg-MYOCY437H mice, as shown by the reduced
outflow facility in these mice (35). A significant increase in outflow
facility at 1 mo after Ad5-crMYOC treatment in a separate cohort
of 4- to 5-mo-old Tg-MYOCY437H mice (Fig. 2C) indicates that
Ad5-crMYOC treatment improves TM cell function in vivo by
disrupting mutantMYOC. The improved TM health and rescue in
the IOP phenotype in Ad5-crMYOC–treated eyes correlates with
the significantly improved RGC function at 1 mo after Ad5-
crMYOC treatment, as measured by pattern electroretinography
(pERG) in a cohort of 4- to 5-mo-old Tg-MYOCY437H mice with a
mean amplitude of 24.644 μV vs. 18.239 μV in Ad5-cas9–treated
eyes (n = 13) (Fig. 2D). Mean pERG values were 26.723 μV and
28.417 μV at 1 mo after Ad5-cas9 and Ad5-crMYOC injection,
respectively, into eyes of 4- to 5-mo-old WTmice, a non-statistically
significant difference (n = 2). Although there was mild self-limited
anterior segment inflammation due to Ad5 injection (even with the
Ad5-null vector) (36), this did not affect the iridocorneal angle (Fig.
S2), IOP, or aqueous outflow facility.
CRISPR-Cas9 Efficiency in Vivo and ex Vivo. Having shown that our
CRISPR gRNA (forMYOC) is both efficient and selective in vitro
(Fig. 1), we then tested the efficiency of the same Ad5-crMYOC
in vivo. Eyes from 4- to 5-mo-old mice were fixed for myocilin and
ER stress marker immunolabeling, or protein was isolated from
TM tissue (with some iris, corneal endothelium, and sclera, re-
ferred to as the “TM ring”) from the eyes at 1 mo after Ad5-
cas9 or Ad5-crMYOC treatment to test CRISPR efficiency in vivo.
TM tissue sections from Ad5-crMYOC–treated eyes showed re-
duced myocilin, KDEL, and CHOP labeling, indicating that the
gRNA is targeting MYOC in vivo (Fig. 3A). The residual myocilin
labeling (red) could be endogenous mouse myocilin that is not
targeted by our gRNA. By quantifying the number of corrected
TM cells in vivo, we found an estimated transduction efficiency of
at least ∼60–70% using Ad5-cas9 and/or Ad5-crMYOC. Of note,
we also found Cas9 expression in the cornea endothelium and
parts of the iris and ciliary body, similar to previous studies with
adenovirus transduction (36–38). Western blot analysis data also
showed reductions in myocilin, BiP, Calnexin, PDI, ATF4, and
CHOP levels, confirming our ICC data indicating gRNA targeting
in Tg-MYOCY437H mice (Fig. 3B). Previous work has shown that
mutant myocilin is able to form homodimers and tetramers as well
as heterodimers with WT myocilin (23). This prevents the normal
secretion of the WT isoform, initiates UPR, and causes glaucoma.
Our Ad5-crMYOC treatment specifically targets human mutant
MYOC in Tg-MYOCY437H mice. The decrease in mutant human
protein in TM tissue lysate correlated with the increased secretion
of mouse WT myocilin in aqueous humor samples of Ad5-
crMYOC–treated eyes (Fig. 3C). Testing this exclusively was dif-
ficult owing to a lack of specific anti-mouse myocilin antibody. The
light myocilin band in the Ad5-cas9 transgenic mice is likely due to
a small amount of secreted WT mouse myocilin. Quantification of
secreted protein showed significantly increased levels of WT
mouse myocilin in the aqueous humor of Ad5-crMYOC–treated
eyes (Fig. 3D). These findings are also supported by the fact that
our gRNA does not target mouse WT Myoc in the mouse kidney
cell line IMCD3 and is highly specific in targeting the human
MYOC human trabecular meshwork cell line NTM5 (Fig. S3).
We further assessed the feasibility of using genome editing to
treat glaucoma in human TM tissues using a human ex vivo ante-
rior segment perfusion culture system (Materials and Methods).
Ad5-crMYOC reduced myocilin mRNA (Fig. 3F) and myocilin
secretion into the perfusate medium (medium in which eyes were
cultured, collected at the end of the experiment) obtained from the
TM outflow pathway compared with the contralateral fellow eye
treated with Ad5-cas9 (Fig. 3E), further supporting the ex vivo
efficiency of Ad5-crMYOC in perfusion-cultured human eyes.
Discussion
Although it has been almost 20 y since the discovery ofMYOC as the
first glaucoma gene (7), the physiological role of the normal MYOC
protein remains unknown. The fact that most MYOC mutations
result in early-onset glaucoma has a much greater impact on quality
of life than typical late-onset POAG. The lack of a discernable
phenotype in Myoc−/− mice and humans with MYOC deletions
suggests that MYOC mutations are gain-of-negative function muta-
tions (16, 17, 19, 20). We previously reported the development of a
mouse model (Tg-MYOCY437H) that replicates the POAG pheno-
type (30). The Tg-MYOCY437H mouse has contributed to our un-
derstanding of the in vivo pathophysiology of myocilin-associated
glaucoma. Unlike WT, mutant myocilin accumulates inside TM
cells, causing ER stress. This chronic ER stress affects the normal
function and/or survival of TM cells, resulting in increased
aqueous humor outflow resistance and leading to elevated IOP.
We have previously shown that a chemical chaperone can be
used to treat Tg-MYOCY437H mice (30). Administration of
phenylbutyric acid (PBA; 20 mM) in drinking water for 5 wk
Fig. 2. CRISPR-Cas9 lowers IOP and prevents further glaucomatous damage.
(A) Ad5-crMYOC (intravitreal injections; 2 × 107 pfu/eye) prevents IOP ele-
vation in ≤1-mo-old Tg-MYOCY437H mice (n = 7–11). (B) Ad5-crMYOC
(intravitreal injections; 2 × 107 pfu/eye) lowers IOP in older (age ≥9 mo) Tg-
MYOCY437H mice (n = 9). (C) Improved or preserved outflow facility in eyes of
4- to 5-mo-old Tg-MYOCY437H mice at 1 mo after Ad5-crMYOC treatment.
The mean facility in these eyes is 0.0468, compared with 0.0309 μL/min/mmHg
in Ad5-cas9–treated eyes (n = 7). (D) Improved retinal ganglion cell function
measured by pERG in eyes of 4- to 5-mo-old Tg-MYOCY437H mice at 1 mo after
Ad5-crMYOC treatment (mean amplitude, 24.644 μV vs. 18.239 μV in Ad5-cas9–
treated eyes; n= 13). Error bars represent SEM. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001, ANOVA with Bonferroni correction or paired Student’s t test.






prevents IOP elevation and also reduces IOP in Tg-MYOCY437H
mice. Although PBA is effective in the MYOC mouse model and
has Food and Drug Administration approval as an oral agent
for urea cycle disorders, the continuous production of mu-
tant myocilin requires chronic administration of PBA to relieve
glaucoma symptoms. In the present study, we sought a more
permanent solution for treatment by using genome editing.
Given the dominant nature of MYOC mutations, we used the
CRISPR-Cas9 system to disrupt the MYOC gene both in vitro
and in vivo in mice. Our construct also works well in cultured
human TM cells and skin fibroblasts in vitro, as well as in human
ex vivo perfusion-cultured eyes, suggesting a feasible trans-
lational application of this technology to humans. Our data show
a genome editing phenotypic response similar to that seen with
the chronic use of PBA in young Tg-MYOCY437H mice (22, 23).
Our findings indicate that genome editing can prevent IOP
elevation and the resulting development of glaucoma, and also
effectively lower IOP in mutantMYOC ocular hypertensive mice.
Using a gRNA specifically directed against the human MYOC
gene, we were able to disrupt the gain of function of mutant
myocilin, lower the misfolded protein load in TM cells, and
rescue ER stress in vitro. Using the same gRNA and CRISPR-
Cas9 assembly in vivo, we were able to prevent the development
of glaucoma in young Tg-MYOCY437H mice before the onset of
symptoms (i.e., elevated IOP). In addition, we were able to use
genome editing to treat glaucoma in older Tg-MYOCY437H mice
that had elevated IOP for 9 mo before treatment. Although we
would expect genome editing to permanently eliminate the ex-
pression of the mutant myocilin protein, our present data do not
address whether the genome-edited TM cells persist indefinitely.
The reduction of elevated IOP in older animals indicates that
TM cells tolerate ER stress without dying for a substantial pe-
riod, potentially providing a broad therapeutic time frame. It is
likely that a pool of stressed TM cells, when corrected, have
better proliferation ability and are able to repopulate the dam-
aged TM. This idea is supported by the increased proliferation in
human skin fibroblasts from patients with myocilin-associated
glaucoma after genome editing (Fig. S4). Ad5-crMYOC–medi-
ated disruption of MYOC in these fibroblasts improved their
proliferative ability, as demonstrated by increased incorporation
of 5-bromo-2′-deoxyuridine (BrdU).
It would have been nice to quantify changes in TM cellularity
in these rescued mice after Ad5-crMYOC treatment, but the
lack of an organized TM structure as well as a TM cell-specific
marker in mice makes this quantification difficult and non-
specific, although we would expect to see an increase in viable
and functional TM cells after disruption of the mutant transgene.
While we were able to preserve RGC function in younger mice,
the reduction of IOP in older mice might not allow significant
RGC recovery owing to the high sensitivity to pressure variation
and irreversible RGC loss. Nonetheless, lowering IOP should
halt any further loss of RGCs, as is achieved by successful drug
therapy in human patients.
It should be noted that in this study, we targeted the first exon,
a target that should be equally effective for numerous different
MYOC mutations. We also could have targeted the promoter or,
alternatively, attempted to use homologous recombination to
correct specific mutations in a given patient. However, the use of
an identical gRNA in patients with different disease-causing
variants may help overcome one potential problem with genome
editing, the off-target effects. One concern associated with the
use of NHEJ-based gene disruption is the possible introduction
of additional mutations that might lead to longer or shorter
protein isoforms; however, we did not observe other myocilin
protein isoforms after Ad5-crMYOC treatment. Importantly, we
have demonstrated the feasibility of CRISPR-Cas9 genome
editing in a human organ. We successfully targeted human
MYOC in ex vivo perfusion-cultured human eyes and reduced
the secreted myocilin protein load. Such ex vivo systems also may
be used to explore and eliminate potential off-target genome
alterations, as well as to further explore Cas9 modifications with
greater on-target efficiency.
Previously reported in vivo uses of CRISPR-Cas9 include cor-
rection of a dominant loss-of-function cataract-causing mutation
in mouse embryos (39), HDR in a mouse model of type I tyrosi-
nemina (40), correction of retinal dystrophy in a rat model of
autosomal dominant retinitis pigmentosa (41), NHEJ-mediated
gene disruption of PCSK9 in the mouse liver (42), and intra-
hepatic hepatitis B virus template clearance (43). Our present
study demonstrates the potential of CRISPR-mediated genome
editing in human myocilin-associated POAG, as well as in other
human disorders resulting from gain-of-function mutations.
Materials and Methods
TM Cell Culture.Human TM cells were isolated from carefully dissected human
TM tissue explants derived from patients with glaucoma or from normal
donors and characterized as described previously (44). All donor tissues were
obtained from regional eye banks after receipt of informed consent from
the donors’ families and were managed according to the guidelines in the
Declaration of Helsinki on research involving human tissue. Isolated TM cells
were grown in DMEM (Invitrogen) containing 0.292 mg/mL L-glutamine (Life
Technologies), 100 U/mL penicillin-0.1 mg/mL streptomycin (Life Technolo-
gies), and 10% FBS (Life Technologies). The stably transformed human TM
cell line NTM5 (45) was also used and cultured in the same medium.
Generation and Characterization of Stable Cell Lines. NTM5 cell lines were
transfected with pDsRedN1-MYOC (WT or Y437H) using LyoVec (InvivoGen).
These plasmids express DsRed at the C terminus of myocilin protein. Once
confluent, the cells were treated with 1.5 μg/mL puromycin (Thermo Fisher
Fig. 3. CRISPR efficiency in vivo in mice and ex vivo
in human eyes. (A) Representative image showing
that Ad5-crMYOC treatment reduces myocilin (red),
KDEL (red), and CHOP (red) levels in the TM
(rectangular box) of Tg-MYOCY437H mice (n = 3).
C, cornea; CB, ciliary body. (Scale bar: 50 μm.)
(B) Representative image of WB samples from a TM
ring showing that Ad5-crMYOC treatment decreases
myocilin levels and associated BiP, Calnexin, PDI,
ATF4, and CHOP protein levels (n = 9). (C) Repre-
sentative image showing increased secretion of
mouse WT myocilin into the aqueous humor of Ad5-
crMYOC–treated eyes compared with Ad5-cas9–
treated eyes. (D) Densitometry showing a significant
increase in the levels of secreted mouse WT myocilin
in Ad5-crMYOC–treated eyes of Tg-MYOCY437H mice
(n = 4). (E) inhibition of myocilin secretion by Ad5-
crMYOC–mediated myocilin knockdown in a human
ex vivo anterior segment perfusion culture (n = 2).
Coomassie blue staining was performed to ensure relatively equal loading. (F) Decreased myocilin (MYOC) mRNA expression in human ex vivo anterior
segment perfusion culture by Ad5-crMYOC treatment. Error bars represent SEM. *P < 0.05.
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Scientific), and at 3–4 wk posttreatment, individual colonies were picked and
expanded. Colonies were characterized using Western blot analysis and Sanger
sequencing; colonies with the highest myocilin expression were used for sub-
sequent experiments. Nontransfected naïve NTM5 cells served as a control.
Design of Human MYOC-Specific gRNA. The human MYOC cDNA sequence at
≈300 bp from the start codon was loaded onto the Genome-Engineering
website (tools.genome-engineering.org). (Note: We did not target the
MYOC genome sequence, because human MYOC cDNA was the transgene
inserted into Tg-MYOCY437H mice.) Several of the most suitable gRNAs,
based on computationally predicted off-target sites for each intended tar-
get, were selected, cloned into px330 (with spCas9) vectors, and tested
for efficiency and selectivity for human MYOC over mouse Myoc. gRNA
(GGCCTGCCTGGTGTGGGATG) with the greatest efficiency in disrupting
MYOC was cloned into a shuttle vector and subsequently into Ad5 vectors
for use in our study. Ad5-cas9 control virus was purchased from Vector
Biolabs (catalog no. 1901). Ad5-cas9 control virus does not contain any gRNA
and expresses only GFP-tagged Cas9. Maps of the shuttle vectors used to
generate these viruses are provided in Figs. S5 and S6.
TM Cell Treatment. Primary human TM cells were grown to 100% confluence
in serum-containing medium. TM cells were incubated with medium con-
taining either Ad5-cas9 (tagged with GFP) or Ad5-crMYOC for 24 h, followed
by incubation in fresh medium for another 24 h.
Mouse Husbandry. Tg-MYOCY437H mice (on a mixed C57BL/6 and A/J back-
ground) were housed and bred at the University of Iowa’s animal research
facility. The mice weremaintained on a 4%-fat NIH 31 diet provided ad libitum
and housed in cages containing dry bedding (Soft-Zorb Enrichment Blend;
Northeastern Products). A temperature of 21 °C and a 12-h light/12-h dark
cycle were maintained. All animal procedures in this study were performed in
compliance with the Association for Research in Vision and Ophthalmology’s
Statement for the Use of Animals in Ophthalmic and Vision Research and were
approved by both the University of Iowa’s Animal Care and Use Committee
and the University of North Texas Health Science Center’s Institutional Animal
Care and Use Committee. Power calculations were performed to determine
the number of mice needed for each experiment.
Intravitreal Injections. Mice were anesthetized with a mouse anesthesia
mixture (ketamine + xylazine). One eye was injected with Ad5-crMYOC (2 ×
107 pfu/eye in a volume of 2 μL of PBS) or Ad5-cas9 through the sclera into
the vitreous chamber using a Hamilton microsyringe fitted with a sterile 33-
gauge needle. The contralateral eye served as a control. The few mice that
developed eye abnormalities were excluded from further study.
IOP Measurements. IOP was measured with a TonoLab rebound tonometer
(Colonial Medical Supply) in a masked manner (i.e., the researcher taking the
reading was unaware of the type of treatment until the very end of the ex-
periment) in two independent cohorts of mice at the University of North Texas
Health Science Center’s and University of Iowa’s animal research facilities.
Mice were anesthetized using 2.5% isoflurane plus 100% oxygen. Daytime
IOP was measured between 8 and 10 AM, and nighttime IOP was measured in
the dark between 9 and 11 AM. The data shown here are for nighttime IOPs.
Outflow Facility Measurements. Aqueous humor outflow facility was mea-
sured after 1 mo of intravitreal virus injections in both eyes of each animal
(age 4–5 mo) by constant flow infusion as described previously (46). In brief,
anesthetized eyes were infused at a flow rate of 0.1 μL/min. Once the
pressure stabilized, pressure measurements were recorded, and flow rate
was increased sequentially to 0.2, 0.3, 0.4, and 0.5 μL/min. Three stabilized
pressures (spaced 5 min apart) at each flow rate were recorded. Mean sta-
bilized pressures were plotted with flow rates, and outflow facility in each
eye was calculated as the reciprocal of the slope of the resulting line.
pERGs. After 1 mo of intravitreal virus injections, retinal ganglion cell func-
tional analysis was performed using a pERG system (Intelligent Hearing
Systems) that records in both eyes simultaneously using snout electrodes as
described previously (47). In brief, 4- to 5-mo-old mice were anesthetized
(ketamine 100 mg/kg; xylazine 10 mg/kg i.p.), placed on a holder to allow
unobstructed vision, and then moved at a fixed distance (10 cm) from the
LED monitors. A constant body temperature of 37 °C was maintained using a
rectal probe and feedback-controlled heating pad. A small amount of sterile
PBS was applied topically to prevent corneal dryness. Visual stimuli consisted
of contrast-reversing bars generated on two LED screens. pERG readings
from each eye were generated simultaneously using an s.c. stainless steel
needle placed in the snout. The reference and ground electrodes were
placed medially on the back of the head and at the root of the tail, re-
spectively. pERG waveforms were generated automatically, and average
amplitude was represented graphically using GraphPad Prism.
Perfusion Anterior Segment Culture of Human Eyes. Human donor eyes were
obtained from the Lions Eye Institute for Transplantation and Research
(Tampa, FL) after receipt of informed consent from the donors’ families. All
donor tissues were managed in accordance with Declaration of Helsinki
guidelines for research involving human tissue. The anterior segments of
paired donor eyes were prepared for ex vivo perfusion culture as described
previously (48, 49). Both Ad5-cas9 and Ad5-crMYOC (1010 pfu) were in-
troduced as a bolus into each eye, followed by perfusion at a constant flow
rate of 2.5 μL/min. Perfusate medium was collected over 4 d of culture and
then subjected to Western blot analysis for myocilin expression. The SDS-
polyacrylamide gels were also stained with Coomassie blue for total proteins
to ensure equal protein loading. TM tissues were isolated, and DNA/RNA was
extracted using the Qiagen AllPrep Kit for further analysis.
RNA Isolation and QRT-PCR. Total RNAwas collected using an RNA isolation kit
(IBI Scientific), and 2 μg of RNA was converted into cDNA using iScript (Bio-
Rad). cDNA samples were diluted in iQ SYBR Green Supermix (Bio-Rad) with
the relevant PCR primers (Table S1) and run on a Bio-Rad CFX96 qPCR sys-
tem. Data were analyzed with the system software.
Western Blot Analysis. Cells were lysed with 1% Triton X-100 (containing
protease inhibitors). For in vivo CRISPR efficiency determination studies,
anterior segment or iridocorneal angle tissues were carefully dissected and
lysed in tandom affinity purification lysis buffer. TM tissues were carefully
dissected from perfusion cultures human anterior segments in the ex vivo
model. In addition, aqueous humor (2–3 μL) was collected from each eye
using a pulled glass capillary and mixed with 20 μL of 1× sodium dodecyl
sulfate-PAGE buffer with reducing agent. Proteins were separated on de-
naturing polyacrylamide gels and then transferred to a nitrocellulose
membrane by electrophoresis. Dried blots were blocked in Odyssey Blocking
Buffer (LI-COR Biosciences), followed by overnight incubation with specific
primary antibodies (Table S2). The membranes were washed with PBS/Tween
buffer (PBST) and then incubated with corresponding IRdye secondary an-
tibodies (LI-COR Biosciences). The proteins were then visualized using the
Odyssey CLx Infrared Imaging System (LI-COR Biosciences), and quantitation
was performed with ImageStudio software (LI-COR Biosciences).
Immunofluorescence Microscopy. TM cells were grown on coverslips in 24-well
plates. At 48 hours after Ad5-crMYOC treatment, the cells were fixed, per-
meabilized, and blocked with SuperBlock (Thermo Fisher Scientific). Al-
ternatively, enucleated mouse eyes were fixed in 4% formaldehyde and
embedded in cryoembedding medium, and 10-μm sections were cut using a
Leica CM3050S cryostat. The sections were then blocked with 5% normal
goat serum. Slides/coverslips were incubated overnight with the appropriate
primary antibodies (Table S2) and then washed with PBS, followed by a 1-h
incubation with the appropriate Alexa Fluor secondary antibodies. Nuclei
were counterstained with Vectashield containing DAPI (Vector Laborato-
ries). Images were captured with a Leica TCS SP8 confocal imaging system.
GeneArt Genomic Cleavage Assay. Genomic DNA was extracted from cells
treated with Ad5-crMYOC or Ad5-cas9. Loci in which the gene-specific double-
strand breaks occurred were amplified by PCR (Table S3). The PCR product was
denatured and reannealed so that mismatches were generated as strands with
an indel reannealed to strands with no indel or a different indel. Themismatches
were subsequently detected and cleaved by detection enzymes (Thermo Fisher
Scientific), and the resulting bands were analyzed by gel electrophoresis.
BrdU Assay. All experiments were conducted with the approval and super-
vision of the University of Iowa’s Internal Review Board (application no.
200202022) in accordance with the Declaration of Helsinki. After receipt of
informed consent, skin biopsy specimens were collected from patients for
use in the generation of fibroblasts as described previously (50–52). Skin
fibroblasts from patients with myocilin-associated glaucoma and age-
matched controls (grown on coverslips in 24-well plates) were subjected to
Ad5-cas9 or Ad5-crMYOC treatment. At 48 h after treatment, BrdU (0.03 μg/mL)
was added to the medium for 1–2 h. Cells were fixed, permeabilized with
1 N HCL, blocked with 0.1% serum albumin, and incubated with anti-BrdU
primary antibody (ab6326; Abcam) at 4 °C overnight. After three washes






with PBS, Alexa Fluor 568 secondary antibody was added, followed by
incubation for 1 h at room temperature. Coverslips were mounted using
Vectashield containing DAPI (Vector Laboratories). Images were captured
using a Leica TCS SP8 confocal imaging system.
Hematoxylin and Eosin Staining. Formalin-fixed enucleated mouse eyes were
washed in PBS, dehydratedwith ethanol, and embedded in paraffin. The eyes
were subsequently sectioned at 5 μm thickness and then stained with he-
matoxylin and eosin (H&E).
Statistics. All data are presented as mean ± SEM. Comparisons between two
groups were conducted using the unpaired one-tailed Student’s t test, and
comparisons among three or more groups were done using one-way ANOVA
with Bonferroni correction. A P value <0.05 was considered significant.
Study Approval. All animal procedures performed in this study were con-
ducted in compliance with the Association for Research in Vision and Oph-
thalmology’s Statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the University of Iowa’s Animal Care and
Use Committee. All experiments involving human skin biopsy specimens
were conducted with the approval of and under the supervision of the
University of Iowa’s Internal Review Board (application no. 200202022) and
were consistent with the principles specified in the Declaration of Helsinki.
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